Immune modifiers in the treatment of bladder cancer.
Morales
A
A
Department of Urology, Queen's University, Kingston, Ontario, Canada.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000283:Administration, Intravesical; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005200:FANFT; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D051379:Mice; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000628:therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D007155:Immunologic Factors; D005200:FANFT